You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
福安藥業(300194.SZ):慶餘堂擬8350萬元取得優諾金22.45%的股份
格隆匯 12-25 20:32

格隆匯12月25日丨福安藥業(300194.SZ)公佈,公司子公司福安藥業集團慶餘堂製藥有限公司(“慶餘堂”)、公司控股股東汪天祥與林殿海、魯江、賈殿村、王松山、王鬆正、王敏於2019年12月25日簽署《股權轉讓及增資協議》。

協議約定:優諾金生物工程(蘇州)有限責任公司(“優諾金”或“標的公司”)按投前3.3億元估值,慶餘堂以4950萬元受讓林殿海、魯江所持標的公司合計15%股份,同時以3400萬元認購標的公司新增註冊資本51.51萬元,合計取得標公司22.45%股份;控股股東汪天祥以800萬元認購新增註冊資本12.12萬元,取得標的公司2.15%股權。

優諾金目前主要從事基因工程藥物研發,聚焦於人用重組蛋白藥物的開發。目前優諾金產品均處於研發階段,尚未上市。注射用重組人血蛋白-生長激素融合蛋白(HSA-rhGH)已經取得臨牀批件。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account